PLACEBO USE IN THE CONTEXT OF INFLAMMATORY BOWEL DISEASE CLINICAL TRIALS

• Published in: Arquivos de gastroenterologia 2020-02, Vol.57 (1), p.87-90
• Main Authors: Lasa, Juan Sebastian, Zubiaurre, Ignacio, Rausch, Astrid, Olivera, Pablo
• Format: Article
• Language: English
• Subjects: Clinical trial; GASTROENTEROLOGY & HEPATOLOGY; Inflammatory bowel diseases; Placebos
• ISSN: 0004-2803; 1678-4219; 1678-4219
• DOI: 10.1590/S0004-2803.202000000-15

Inflammatory bowel disease comprises two distinct conditions - Crohn's disease and ulcerative colitis - which can be treated with immunomodulators. A non-neglectable proportion of these patients will need biologic therapy, and many patients under biologic treatment will experience either primary or secondary failure. As a consequence, clinical trials evaluating new therapeutic alternatives are being developed. These trials share common features, such as being controlled with placebo. Placebo use in clinical trials is a matter of intense debate. Those who support placebo use highlight the methodologic advantages placebo-controlled trials have. Those against placebo use argue that it would be against ethical principles in clinical research to expose a patient to placebo when a valid therapeutic alternative exists. In this review, we summarize the existing arguments for and against the use of placebo in the context of inflammatory bowel disease research. We finally suggest that it is very likely that in the near future inflammatory bowel disease trials will no longer be controlled with a placebo arm, but instead they will be non-inferiority trials with an active comparator.